# Project 4: Neoadjuvant Clinical Trial with Pembrolizumab for Locally Advanaced Squamous Cell Carcinoma (SCC)

> **NIH NIH P50** · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · 2024 · $381,600

## Abstract

This is a phase II single-arm neoadjuvant pembrolizumab trial in patients with PD-1 naïve resectable locally advanced SCC.

## Key facts

- **NIH application ID:** 11175542
- **Project number:** 5P50CA254865-04
- **Recipient organization:** UNIVERSITY OF PITTSBURGH AT PITTSBURGH
- **Principal Investigator:** John Munn Kirkwood
- **Activity code:** P50 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $381,600
- **Award type:** 5
- **Project period:** 2024-07-01 → 2026-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11175542

## Citation

> US National Institutes of Health, RePORTER application 11175542, Project 4: Neoadjuvant Clinical Trial with Pembrolizumab for Locally Advanaced Squamous Cell Carcinoma (SCC) (5P50CA254865-04). Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/grant/nih/11175542. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*